Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab with Trifluridine/Tipiracil and Bevacizumab in Refractory mCRC
NCT06060704Phase 2Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Nov 2023
- Primary completion
- Mar 2025
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of envafolimab in metastatic colorectal cancer (mCRC), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Objective Response Rate at 12 months. Status: unknown.
02
Drugs
envafolimab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06060704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06060704.